Hubei Hongyuan Pharmaceutical Technology Past Earnings Performance
Past criteria checks 1/6
Hubei Hongyuan Pharmaceutical Technology has been growing earnings at an average annual rate of 1.4%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 9.7% per year. Hubei Hongyuan Pharmaceutical Technology's return on equity is 1.2%, and it has net margins of 2.7%.
Key information
1.4%
Earnings growth rate
1.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 9.7% |
| Return on equity | 1.2% |
| Net Margin | 2.7% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Hubei Hongyuan Pharmaceutical Technology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,977 | 54 | 102 | 74 |
| 31 Dec 23 | 2,055 | 87 | 96 | 69 |
| 30 Sep 23 | 2,288 | 159 | 106 | 74 |
| 30 Jun 23 | 2,160 | 197 | 101 | 64 |
| 31 Mar 23 | 2,116 | 323 | 98 | 64 |
| 01 Jan 23 | 2,064 | 435 | 107 | 64 |
| 30 Sep 22 | 1,774 | 520 | 106 | 55 |
| 30 Jun 22 | 1,780 | 598 | 112 | 57 |
| 31 Mar 22 | 1,680 | 572 | 107 | 50 |
| 01 Jan 22 | 1,578 | 494 | 109 | 49 |
| 01 Oct 21 | 1,452 | 414 | 99 | 48 |
| 30 Jun 21 | 1,325 | 334 | 89 | 46 |
| 31 Mar 21 | 1,314 | 295 | 93 | 45 |
| 01 Jan 21 | 1,303 | 257 | 97 | 45 |
| 01 Oct 20 | 1,366 | 224 | 109 | 46 |
| 30 Jun 20 | 1,429 | 191 | 120 | 48 |
| 31 Mar 20 | 1,501 | 253 | 126 | 51 |
| 31 Dec 19 | 1,574 | 314 | 132 | 54 |
| 30 Sep 19 | 1,545 | 273 | 135 | 51 |
| 30 Jun 19 | 1,516 | 232 | 138 | 49 |
| 31 Mar 19 | 1,423 | 122 | 131 | 45 |
| 31 Dec 18 | 1,329 | 12 | 124 | 40 |
| 30 Jun 18 | 1,228 | 26 | 112 | 53 |
| 31 Mar 18 | 1,237 | 29 | 124 | 47 |
| 31 Dec 17 | 1,278 | 33 | 136 | 40 |
| 30 Sep 17 | 1,254 | 47 | 149 | 20 |
| 30 Jun 17 | 1,229 | 60 | 163 | 0 |
| 31 Mar 17 | 1,152 | 63 | 161 | 0 |
| 31 Dec 16 | 1,075 | 65 | 160 | 0 |
| 30 Sep 16 | 1,014 | 64 | 148 | 0 |
| 30 Jun 16 | 975 | 70 | 135 | 0 |
| 31 Mar 16 | 989 | 67 | 128 | 0 |
| 31 Dec 15 | 1,003 | 65 | 124 | 0 |
| 30 Sep 15 | 1,037 | 77 | 113 | 0 |
| 30 Jun 15 | 1,026 | 71 | 114 | 0 |
| 31 Mar 15 | 1,017 | 65 | 106 | 0 |
| 31 Dec 14 | 1,031 | 66 | 95 | 0 |
| 31 Dec 13 | 947 | 28 | 79 | 0 |
Quality Earnings: 301246 has a high level of non-cash earnings.
Growing Profit Margin: 301246's current net profit margins (2.7%) are lower than last year (15.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301246's earnings have grown by 1.4% per year over the past 5 years.
Accelerating Growth: 301246's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 301246 had negative earnings growth (-83.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.1%).
Return on Equity
High ROE: 301246's Return on Equity (1.2%) is considered low.